Phase II Trial Results

RNS Number : 5778U

Oxford Biomedica PLC

16 May 2008

 



For Immediate Release	16 MAY 2008

OXFORD BIOMEDICA ANNOUNCES TROVAX® PHASE II TRIAL RESULTS IN RENAL CANCER TO BE PRESENTED AT ASCO

Oxford, UK - 16 May 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces today that updated results from Phase II trials of TroVax in renal cancer will be reported in three presentations at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held 30 May to 3 June in Chicago, Illinois. The presentations are as follows:

Oral presentation entitled: 'Effector and regulatory T cell responses correlate with clinical outcome in metastatic renal cell carcinoma patients treated with MVA-5T4 vaccine and high-dose interleukin-2', on Saturday, 31 May at 3.15pm EDT (session: Developmental Therapeutics Immunotherapy; location: W375a; abstract number: 3004).

Poster presentation entitled: 'Vaccination of renal cell cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) and low-dose interleukin-2: A Phase II trial', on Saturday, 31 May from 8.00am to 12.00pm EDT (session: Gastro-urinary Cancer; location S Hall A1; poster number: 5D; abstract number: 5101).

Poster presentation entitled: 'Vaccination of renal cell cancer patients with TroVax (modified vaccinia ankara delivering the tumor antigen 5T4) plus interferon-alpha: A Phase II trial', on Sunday, 1 June from 2.00pm to 6.00pm EDT (session: Developmental Therapeutics Immunotherapy; location: S Hall A1; poster number: 17F; abstract number: 3053).

The presentations will provide updated results from three Phase II trials of TroVax in over 60 patients with metastatic renal cancer. The results include data on safety, immune responses and clinical benefit.

The abstracts can be accessed online at http://www.asco.org. 

-Ends-

For further information, please contact:
Oxford BioMedica plc:  Professor Alan Kingsman, Chief Executive	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Holly Griffiths/ Katja Stout/ Claire Mosley College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. 

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax®, a therapeutic vaccine for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 85. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. 

Further information is available at www.oxfordbiomedica.co.uk

2. TroVax® 

TroVax is Oxford BioMedica's novel therapeutic cancer vaccine, which is being developed in collaboration with sanofi-aventis. It is designed specifically to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a Modified Vaccinia Ankara vector, which delivers the gene for 5T4 and stimulates a patient's body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4.

 

END

 

 

RESFKPKQQBKDFPD